UCSF MIBG Protocol

Here are the files for the UCSF Phase II high-dose 131I-MIBG compassionate use protocol for treatment of patients having malignant pheochromocytomas or paragangliomas.

    In order for 131I-MIBG therapy to achieve a remission for patients with malignant pheochromocytoma, the tumors must have sufficient uptake of MIBG on diagnostic scans to allow enough131I-MIBG to enter tumor cells. Treatment doses up to 500 mCi131I-MIBG can be given without cryopreserved blood stem cells. At higher doses, there is a significant risk of severe suppression of the bone marrow. However, peripheral blood stem cell leukophoresis and cryopreservation has made it possible to treat patients with malignant pheochromocytoma more aggressively with 131I-MIBG, since peripheral blood stem cells may be collected in advance and reinfused in the event of prolonged myelosuppression following high-dose 131I-MIBG therapy.

    This entry was posted in I-131-MIBG Treatment. Bookmark the permalink.

    Comments are closed.